About

Copious research efforts have been undertaken in MS research in the last three decades to unravel immune mechanisms in the periphery thought to be responsible for disease onset and effector mechanisms mediating CNS damage.  However, the underlying molecular causes of MS are still not understood and prognostic estimates can hardly be given to patients in the absence of valid surrogate markers.  Traditional therapeutic disease modifying regimens aim at immunomodulation or immunosuppression and were developed in the context of autoimmune research in conjunction with other diseases such as rheumatoid arthritis, Crohn’s disease and diabetes mellitus.  However, response to anti-inflammatory therapeutic interventions differs significantly between MS and other autoimmune disorders.  Moreover, in many MS patients, response to the current interventions has only limited impact on disease progression.  Finally, novel therapies in MS aimed at reducing the CNS-directed immune responses are associated with a severe risk for opportunistic CNS infection.

There is currently an urgent need to go back to basics and apply completely novel ideas and unconventional methods as well as brand new technologies to research in this area.  Now is the time to take up the challenge and, for the first time in Germany, promote interaction between strong research groups at three different sites that all have the ideal prerequisites for illuminating and expanding highly novel and innovative perspectives in MS research.  The goal of this consortium, which consists of scientists from centers in the Rhine-Main area, Münster and Munich, is to unravel the pathology of MS and develop as well as understand novel therapeutic concepts.  The ideal prerequisites for such progress are provided by effectively linking scientists from neighboring disciplines with classical neuroimmunologists, who possess a proven track record in MS research and patient care and arise from an important and internationally visible nucleus in this field.  One key aspect here is the strong bidirectional crosstalk between pure experimental research in animal models and clinical research in human systems and patients, which allows the best transfer of basic knowledge into clinical care – and vice versa.

News

Tue, 09/10/2018
High-ranking Lectures on Immunotherapy and its risks
Muenster. The Department of Neurology Muenster is pleased to announce its Neurology Seminar with guest lecturers Prof. Stephen Reddel and Prof. Helmut Butzkueven. Professor Stephen Reddel’s talk will focus on immunosuppression safety. Reddel is a staff specialist neurologist at Concord Repatriation & General Hospital Sydney, consultant neurologist at the Brain & Mind Centre, University of […]...more
Tue, 09/10/2018
Munich Cluster for Systems Neurology (SyNergy) will be funded
Munich. The Cluster for Systems Neurology (SyNergy) by LMU and TUM will receive funding from 2019 on. Currently SFB PIs Prof. Reinhard Hohlfeld, Prof. Martin Kerschensteiner, Prof. Mikael Simons are also PIs of SyNergy projects....more
Fri, 31/08/2018
Women in Science Network Conference “Decision Making in Infection and Immunity”
The female scientists invite you to the Women-in-Science Network Conference Münster 2018, co-funded by the SFB TR-128. This conference taking place on November 27 and 28 has two main goals: (1) to present and discuss top-level scientific contributions and (2) to increase visibility, encourage leadership, and provide a strong community for women in science. The […]...more